Evidence map›Paper›PMID 37550601›Full record

ArticleMolecular diversity2024

Identification of potent anti-immunogenic agents through virtual screening, 3D-QSAR studies, and in vitro experiments.

Mamona Mushtaq, Saman Usmani, Almas Jabeen, Mohammad Nur-E-Alam, Sarfaraz Ahmed, Aftab Ahmad, Zaheer Ul-Haq

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mamona MushtaqDr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS,, University of Karachi, Karachi, 75270, Pakistan.
Saman UsmaniDr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS,, University of Karachi, Karachi, 75270, Pakistan.
Almas JabeenDr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS,, University of Karachi, Karachi, 75270, Pakistan.
Mohammad Nur-E-AlamDepartment of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box. 2457, Riyadh, 11451, Kingdom of Saudi Arabia.
Sarfaraz AhmedDepartment of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box. 2457, Riyadh, 11451, Kingdom of Saudi Arabia.
Aftab AhmadDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, 92618, USA.
Zaheer Ul-HaqDr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS,, University of Karachi, Karachi, 75270, Pakistan. zaheer.qasmi@iccs.edu.

Funding

King Saud University RSP2023R380
6 · The paper itself

Abstract

A wealth of literature has highlighted the discovery of various immune modulators, frequently used in clinical practice, yet associated with numerous drawbacks. In light of this pharmacological deficiency, medical scientists are motivated to develop new immune modulators with minimized adverse effects yet retaining the improved therapeutic potential. T-cell differentiation and growth are central to human defense and are regulated by interleukin-2 (IL-2), an immune-modulatory cytokine. However, scientific investigation is hindered due to its flat binding site and widespread hotspot residues. In this regard, a prompt and logical investigation guided by integrated computational techniques was undertaken to unravel new and potential leads against IL-2. In particular, the combination of score-based and pharmacophore-based virtual screening approaches were employed, reducing the data from millions of small molecules to a manageable number. Subsequent docking and 3D-QSAR prediction via CoMFA further helped remove false positives from the data. The reliability of the model was assessed via standard metrics, which explain the model's fitness and the robustness of the model in predicting the activity of new compounds. The extensive virtual screening herein led to the identification of a total of 24 leads with potential anti-IL-2 activity. Furthermore, the theoretical findings were corroborated with in vitro testing, further endorsing the anti-inflammatory potential of the identified leads.

Indexed as

Interleukin-2Molecular Docking SimulationQuantitative Structure-Activity RelationshipDrug Evaluation, PreclinicalHumansImmunologic FactorsImmunologic FactorsInterleukin-23D-QSARAutoimmune disordersInterleukin-2Small molecule inhibitorsVirtual screening

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.